Strategic procurement in clinical trials: A digital transformation imperative
Clinical trial procurement is moving from a narrow, transactional "buying" function to a strategic capability that shapes speed,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Guest Blogs
Can Indian biosimilars and generics restate accessibility in global underserved markets?
Pharmacy of the world, a name that India has earned through the provision of low-cost, quality generics to patients…
Beyond the ladder: Why sustainable growth needs to be T-shaped and self-driven
If one looks at the organisations that have excelled in their core operating areas and also considered as employers of choice, one…
Pharma trends that will shape 2026: Building a future-ready, patient-centric industry
As we move closer to 2026, the pharmaceutical ecosystem is undergoing a profound transformation driven by digital innovation,…
Inside the world of pharma consulting: The career that teaches you to think differently
When a survey by TCS and the Association of Management Consulting Firms revealed that nearly 80% of MBA students in India aspired…
India’s Pharma 2047: How academia can drive innovation and self-reliance
As India marches toward its 2047 vision of becoming an innovation-led, self-reliant pharmaceutical powerhouse, the role of…
Clinical research careers: India’s next big opportunity
With the global healthcare and life sciences sector set to cross USD 4.28 billion by 2033, India has emerged as one of the…
Nimesulide and patient safety: Lessons from global drug regulation
Recently, the Indian Ministry of Health and Family Welfare issued a government resolution banning the use of Nimesulide above 100…
Leadership imperative shaping India’s healthcare and pharma landscape in 2026
India’s healthcare and pharmaceutical industries stand at an inflection point. The sector grew at a remarkable 17.5 per cent CAGR…
Advanced excipients could emerge as India’s next big pharma advantage
When the Central Drugs Standard Control Organization (CDSCO) revised Good Manufacturing Practice norms under Schedule M in…
2025 in review: How India pharma rewired its deal playbook
India’s pharmaceutical sector has continued to attract sustained investor interest, even amid periods of broader market…
Cleanliness, innovation, and policy can make India a global leader against AMR: Dr Abdul Ghafur
In an open letter addressed to Prime Minister Narendra Modi, Dr Abdul Ghafur, coordinator of the Chennai Declaration and…
Pharma Outlook 2026: India’s leap from ‘World’s Pharmacy’ to ‘World’s Innovation Partner’
Ahead of 2026, Bhavin Mehta highlights how India’s pharma sector is moving from volume-led supply to value-driven global…
The role of cold-chain-ready, in-city warehousing in strengthening India’s pharma logistics
Adarsh Padmanabha highlights how cold-chain-ready, in-city warehousing is reshaping compliance, speed, and reliability across…
Affordable ORS for all: Industry’s imperative to align with WHO’s vision and recent regulatory…
Mahesh Patil explains why the pharmaceutical industry must realign ORS formulation, packaging, and pricing with WHO guidance and…
Urgent reforms to ensure safe medicines: Need of the hour
Dr Suresh Saravdekar, former Assistant Director, Ministry of Medical Education and Health, State of Maharashtra, and Honorary…
Green Pharma: How the industry can reduce its carbon footprint without compromising growth
Dr Supriya Shidhaye outlines how the pharma industry can shrink emissions while maintaining output and market expansion
The development of medico-legal governance in pharma companies
While the field of global healthcare is transforming at a breakneck pace, the pharmaceutical industry finds itself at a critical…
India’s labour code overhaul: A step forward with shadows still unseen
Applauding the Reform Momentum
India’s recent labour reforms mark a historic step. The Indian Government put into effect four…
Manufacturing permissions after lapse of new drug status: A critical review
As per NDCT Rules under Rule 2 (w) subclause (v) "new drug" means, (v), shall continue to be new drugs for a period of four years…